Secukinumab outcomes in Canadians with hidradenitis suppurativa

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational, non-interventional study follows adults in Canada with dermatologist-diagnosed moderate-to-severe hidradenitis suppurativa who have been newly prescribed secukinumab as part of routine care. The protocol captures baseline characteristics, treatment patterns, and safety outcomes, with first treatment occurring no more than seven days before the baseline visit. Patients must give informed consent and understand English or French, and participation takes place at Novartis investigative sites in Calgary, Winnipeg, and Fredericton. No additional study-mandated treatments are given; clinicians manage therapy per usual practice and outcomes are recorded over time.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Patients must give written, signed, and dated informed consent before any information is collected and any study-related activity is performed.
2. Adult patients at the time of informed consent signature.
3. Patients with the diagnosis of moderate-to-severe HS, as determined by the dermatologist.
4. Patients who have been newly prescribed secukinumab as part of routine clinical care according to the approved Canadian PM. The decision to prescribe secukinumab must be made prior to,and independent of, study participation. First treatment with secukinumab must occur no more than 7 days (≤7 days) prior to Baseline visit.
5. Patients who can understand written and spoken Canadian English or French.

Exclusion Criteria:

1. Any medical or psychological condition in the treating physician's opinion that may prevent the patient from study participation.
2. Patients who have any contraindications to treatment with secukinumab, as defined in the Canadian PM.
3. Patients who have had any prior exposure to secukinumab (i.e., \>7 days prior to the baseline visit).

Where it's running

• Novartis Investigative Site
  Calgary, Alberta, Canada Recruiting
• Novartis Investigative Site
  Calgary, Alberta, Canada Recruiting
• Novartis Investigative Site
  Winnipeg, Manitoba, Canada Recruiting
• Novartis Investigative Site
  Fredericton, New Brunswick, Canada Recruiting
• Novartis Investigative Site
  St. John's, Newfoundland and Labrador, Canada Recruiting
• Novartis Investigative Site
  Cobourg, Ontario, Canada Recruiting

Study contacts

• Study coordinator: Novartis Pharmaceuticals
• Email: novartis.email@novartis.com
• Phone: +41613241111

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Long-term real-world tracking of secukinumab treatment for moderate to severe hidradenitis suppurativa in Italy

  This project will see how secukinumab works and is used in adults with moderate to severe hidradenitis suppurativa in Italy.

  Recruiting at 16 sites Novartis · Ancona, AN and 15 other locations · NCT07543419

• Post-marketing surveillance of Cosentyx (secukinumab) for hidradenitis suppurativa, pediatric plaque psoriasis, and juvenile idiopathic arthritis in Korea

  This study will see how Cosentyx (secukinumab) works and is tolerated in people in Korea with moderate-to-severe hidradenitis suppurativa, pediatric plaque psoriasis, or juvenile idiopathic arthritis who are being treated in routine care.

  Recruiting Novartis · Seoul, Seoul · NCT07243782

• BTK inhibitor remibrutinib in hidradenitis suppurativa shows how it works in adults

  This phase 1 trial tests whether remibrutinib can safely affect HS in adults with moderate to severe disease.

  Recruiting at 2 sites Phase 1 Novartis · San Diego, California and 1 other locations · NCT07855276

• Olatorepatide vs placebo for adults with moderate-to-severe hidradenitis suppurativa who are overweight

  This study tests whether olatorepatide can help people with hidradenitis suppurativa who are overweight or obese.

  Recruiting Phase 2 Regeneron Pharmaceuticals · The Bronx, New York · NCT07830329

• Secukinumab retention in adults with plaque psoriasis and MASLD in Spain

  This study tests how long people with plaque psoriasis and MASLD stay on secukinumab in real-world Spain, using EMR data from several hospitals.

  Recruiting at 9 sites Novartis · Badalona, Barcelona and 8 other locations · NCT07683065

• Remibrutinib extension study for adults with moderate to severe hidradenitis suppurativa

  This extension study tests whether continuing remibrutinib is safe and helps skin symptoms in adults who completed prior HS trials.

  Recruiting at 61 sites Phase 3 Novartis · Birmingham, Alabama and 60 other locations · NCT07665437

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.